Tolterodine in the treatment of overactive bladder: analysis of the pooled phase II efficacy and safety data.
about
Which anticholinergic drug for overactive bladder symptoms in adultsAnticholinergic drugs versus placebo for overactive bladder syndrome in adultsWhich anticholinergic drug for overactive bladder symptoms in adultsDetrusor instability; day and night time wetting, urinary tract infections.The overactive bladder.Tolterodine extended release in the treatment of male OAB/storage LUTS: a systematic review.Evidence for the efficacy and safety of tolterodine in the treatment of overactive bladder.Ketoconazole inhibits the metabolism of tolterodine in subjects with deficient CYP2D6 activityTolterodine for the treatment of overactive bladder.Role of fesoterodine in the treatment of overactive bladder.Tolterodine reduces veratridine-augmented late INa, reverse-INCX and early afterdepolarizations in isolated rabbit ventricular myocytes.Fesoterodine for the treatment of urinary incontinence and overactive bladder.Clinical study results of tolterodine in patients with overactive bladder.Tolterodine for the treatment of urge urinary incontinence.Tolterodine in the Treatment of Male LUTS.The overactive bladder in children: a potential future indication for tolterodine.Food increases the bioavailability of tolterodine but not effective exposure.Tolterodine: a safe and effective treatment for older patients with overactive bladder.Tolterodine and its active 5-hydroxymethyl metabolite: pure muscarinic receptor antagonists.A randomized controlled trial of tolterodine and oxybutynin on tolerability and clinical efficacy for treating Chinese women with an overactive bladder.Pressure-flow variables in patients treated with tolterodine for detrusor overactivity.
P2860
Q24203880-FA067EC9-BC50-4A63-8E0D-E735800960C4Q24243870-E24CDD4A-C5C8-4917-8CA2-EA86FF663CD2Q24246651-1CD9800D-DFD7-4B81-B98E-63C05E6D04A3Q33975485-CEBA6CB8-7884-4C2E-AAEB-08C435C5868CQ34304443-C1CAA38F-C382-49AB-B252-1AAD6ADF6D1FQ34502903-34D3FD02-CFCA-46A8-923E-468521B26B37Q34515443-BE499A1F-079D-4C0E-B713-BA6E17E9E7DDQ36053831-3205F7C7-EFD6-44ED-A414-1276FFA7B4E3Q37142090-1A508E85-789D-4A55-BCEF-915CEA44F543Q37283542-97990C29-D410-4A50-A294-446CF02D7A49Q37399383-B50A77CC-55C9-4060-A14E-A6FF07F612FEQ37429813-543F5F74-5F58-4DBA-A861-674E6EAFE698Q37610148-D2A99CD0-D8D2-41B0-9E03-C4B49ACB390CQ38124056-AEC86525-6F5C-484D-B42C-4B6FD00D7590Q38543432-4D0F5EB6-35FF-4F66-9EB9-674B6A9FCAD1Q40714098-B1AB9DD4-D6EB-42FE-A0CE-45A3B73DC7ADQ43554154-DA2EA1EC-8EF4-469D-BC46-48642B104511Q43674684-FD4AA5C8-B481-4840-945D-93E1BF781023Q44036364-6FB160A6-CB96-4A7C-A879-F32B5BB865ECQ44099874-B6D2A108-50DC-4416-8B97-5272AAEB639FQ44665449-35978FB8-A77E-4DC5-91D8-FC1F0890B405
P2860
Tolterodine in the treatment of overactive bladder: analysis of the pooled phase II efficacy and safety data.
description
1999 nî lūn-bûn
@nan
1999 թուականի Մայիսին հրատարակուած գիտական յօդուած
@hyw
1999 թվականի մայիսին հրատարակված գիտական հոդված
@hy
1999年の論文
@ja
1999年論文
@yue
1999年論文
@zh-hant
1999年論文
@zh-hk
1999年論文
@zh-mo
1999年論文
@zh-tw
1999年论文
@wuu
name
Tolterodine in the treatment o ...... e II efficacy and safety data.
@ast
Tolterodine in the treatment o ...... e II efficacy and safety data.
@en
type
label
Tolterodine in the treatment o ...... e II efficacy and safety data.
@ast
Tolterodine in the treatment o ...... e II efficacy and safety data.
@en
prefLabel
Tolterodine in the treatment o ...... e II efficacy and safety data.
@ast
Tolterodine in the treatment o ...... e II efficacy and safety data.
@en
P2093
P1433
P1476
Tolterodine in the treatment o ...... e II efficacy and safety data.
@en
P2093
P304
P356
10.1016/S0090-4295(98)00629-3
P407
P577
1999-05-01T00:00:00Z